Japan-based Otsuka Medical Devices, a subsidiary of Otsuka group, and its holding company Otsuka Holdings have entered into a merger agreement with US-based medical device firm ReCor Medical.

Under the terms of the agreement, which is subject to shareholder approval, Otsuka Holdings will buy the remaining shares in ReCor from French venture capital firm Sofinnova Partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ReCor designs and manufactures an ultrasound ablation device called Paradise System for renal denervation (RDN).

“Under the terms of the agreement, which is subject to shareholder approval, Otsuka Holdings will buy the remaining shares in ReCor from French venture capital firm Sofinnova Partners.”

The company obtained the US Food and Drug Administration (FDA) approval last month to evaluate the safety and effectiveness of Paradise Renal Denervation System for decreasing blood pressure in hypertensive patients.

During the previous RADIANCE-HTN SOLO study in subjects with hypertension, the system met the primary efficacy endpoint of statistically significant blood pressure reduction.

Otsuka Holdings president and representative director Tatsuo Higuchi said: “Our decision today reflects not only ReCor’s excellent clinical results but also the close relationship we have built over the years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our acquisition of ReCor represents an important step forward for Otsuka’s medical device business, leveraging an innovative technology with Otsuka’s expertise in pharmaceuticals and clinical development.”

After the completion of the merger, ReCor will continue developing and assessing the Paradise System in hypertension to support its plans for global commercialisation.

In addition, the system will be investigated for other clinical applications, including heart failure, kidney disease and metabolic conditions.

ReCor Medical president and CEO Andrew Weiss said: “We are excited to move forward in our collaboration with Otsuka to make the Paradise Renal Denervation System a standard of care for treatment of hypertensive patients worldwide.”

ReCor will also help construct Otsuka Medical Devices’ incubation and clinical development hub in the US and Europe.